Close Menu

RNAi

NEW YORK (GenomeWeb) — Regulus Therapeutics announced this week that it has closed its previously announced public stock offering, raising $103.5 million through the transaction.

NEW YORK (GenomeWeb) — Arcturus Therapeutics this week announced that it has established its own office and laboratory space in San Diego to support its RNA drug discovery and development efforts.

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals announced this week that it has completed enrollment in a Phase II trial of its subcutaneously administered TTR-mediated amyloidosis (ATTR) drug revusiran, formerly known as ALN-TTRsc.

NEW YORK (GenomeWeb) – As part of their effort to develop an RNAi-based therapy for hepatitis B infection, researchers from the University of the Witwatersrand in South Africa have developed self-inactivated lentiviral vectors that generate liver-specific microRNA-based RNAi activators that targe

Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinatorial Cloning
Patent Number: 8,877,435

NEW YORK (GenomeWeb) – Rosetta Genomics today announced a deal to sell tests from Admera Health to oncologists and pathologists.

NEW YORK (GenomeWeb) — Isis Pharmaceuticals and Santaris Pharma are currently negotiating a settlement to their roughly three-year-old patent-infringement lawsuit and believe there is "strong potential to settle" the litigation instead of going to trial, according to court documents filed this mo

NEW YORK (GenomeWeb) — A team of scientists from the Scripps Research Institute this week reported the crystal structure of a microRNA bound to human Argonaute 2 both before and after their engagement with a target mRNA, showing how the protein starts off by exposing only a small portion of its g

NEW YORK (GenomeWeb) — A team led by MD Anderson Cancer Center researchers this month published new data demonstrating that breast cancer-derived exosomes are capable of cell-independent microRNA biogenesis and are able to promote tumorigenesis in a Dicer-dependent manner.

NEW YORK (GenomeWeb) — Alnylam Pharmaceuticals this week announced that it has filed an application with UK regulators to begin a Phase I trial of ALN-PCSsc, a subcutaneously administered siRNA treatment for hypercholesterolemia.

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.